Oak Family Advisors LLC Has $248,000 Stock Position in ResMed Inc. (NYSE:RMD)

Oak Family Advisors LLC decreased its holdings in ResMed Inc. (NYSE:RMD) by 81.0% during the 4th quarter, HoldingsChannel reports. The firm owned 1,086 shares of the medical equipment provider’s stock after selling 4,638 shares during the quarter. Oak Family Advisors LLC’s holdings in ResMed were worth $248,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. True Wealth Design LLC lifted its stake in ResMed by 2,200.0% in the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 110 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in ResMed during the 3rd quarter worth $34,000. Rosenberg Matthew Hamilton bought a new position in ResMed in the fourth quarter valued at about $54,000. Capital Performance Advisors LLP acquired a new stake in shares of ResMed during the third quarter valued at about $60,000. Finally, Venturi Wealth Management LLC grew its holdings in shares of ResMed by 55.7% during the third quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 122 shares during the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research report on Friday. Royal Bank of Canada lifted their price objective on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research note on Friday, October 25th. The Goldman Sachs Group started coverage on shares of ResMed in a report on Thursday, January 16th. They set a “buy” rating for the company. Piper Sandler lifted their target price on shares of ResMed from $252.00 to $260.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, KeyCorp lifted their price objective on ResMed from $266.00 to $280.00 and gave the stock an “overweight” rating in a research report on Friday. One analyst has rated the stock with a sell rating, six have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and a consensus price target of $244.73.

ResMed Price Performance

Shares of NYSE:RMD opened at $236.66 on Monday. The company has a 50-day moving average price of $240.17 and a two-hundred day moving average price of $236.41. The firm has a market capitalization of $34.74 billion, a PE ratio of 27.94, a P/E/G ratio of 1.69 and a beta of 0.70. ResMed Inc. has a twelve month low of $170.56 and a twelve month high of $263.05. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. Equities analysts forecast that ResMed Inc. will post 9.41 EPS for the current year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Thursday, February 13th. ResMed’s dividend payout ratio is currently 25.03%.

Insider Transactions at ResMed

In other ResMed news, insider Justin Leong sold 6,160 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $243.09, for a total transaction of $1,497,434.40. Following the completion of the sale, the insider now directly owns 21,718 shares in the company, valued at $5,279,428.62. This represents a 22.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Witte Jan De sold 796 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the completion of the sale, the director now directly owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,030 shares of company stock valued at $2,702,687. Insiders own 0.71% of the company’s stock.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.